Evidence map›Paper›PMID 31415794›Full record

ArticleMolecular and cellular endocrinology2019

Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH).

Lu Han, Stefanie Bittner, Dachuan Dong, Yuan Cortez, Hunter Dulay, Sara Arshad, Wen-Jun Shen, Fredric B Kraemer, Salman Azhar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Review
  2. Review
  3. Phytochemical Compounds and Pharmacological Properties ofMolecules (Basel, Switzerland) · 2022
    Review
  4. Gigantol ameliorates CClScientific reports · 2020
    Article
  5. Carbon tetrachloride (CClBMC gastroenterology · 2020
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lu HanGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA.
Stefanie BittnerGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA.
Dachuan DongGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA.
Yuan CortezGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA.
Hunter DulayGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA.
Sara ArshadGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA.
Wen-Jun ShenGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA. Electronic address: wenjun@stanford.edu.
Fredric B KraemerGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA; Stanford Diabetes Research Center, USA.
Salman AzharGeriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, CA, USA; Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, CA, USA; Stanford Diabetes Research Center, USA. Electronic address: salman.azhar@va.gov.
VA Palo Alto Health Care System · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI MANISHA DESAI · 2017 to 2026
$19.5M
Hypo-Lipidemic Actions of Creosote Bush-Derived NDGAR01HL092473 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI AZHAR, SALMAN · 2009 to 2013
$1.8M
LipolysisI01BX000398 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI KRAEMER, FREDRIC B. · 2009 to 2020
–
Role of Cholesterol in Age-related Decline in SteroidogenesisI01BX001923 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI AZHAR, SALMAN · 2013 to 2020
–
BLRD VA I01 BX000398BLRD VA I01 BX001923NHLBI NIH HHS R01 HL092473NIDDK NIH HHS P30 DK116074
6 · The paper itself

Abstract

Creosote bush (Larrea tridentata)-derived nordihydroguaiaretic acid (NDGA) was shown to have profound effects on the core components of metabolic syndrome. This study investigated the in vivo potential of NDGA for prevention or attenuation of the pathophysiologic abnormalities of NASH. A novel dietary NASH model with feeding C57BL/6J mice with a high trans-fat, high cholesterol and high fructose (HTF) diet, was used. The HTF diet fed mice exhibited obesity, insulin resistance, hepatic steatosis, fibrosis, inflammation, ER stress, oxidative stress, and liver injury. NDGA attenuated these metabolic abnormalities as well as hepatic steatosis and fibrosis together with attenuated expression of genes encoding fibrosis, progenitor and macrophage markers with no effect on the levels of mRNAs for lipogenic enzymes. NDGA increased expression of fatty acid oxidation genes. In conclusion, NDGA exerts anti-NASH/anti-fibrotic actions and raises the therapeutic potential of NDGA for treatment of NASH patients with fibrosis and other associated complications.

Indexed as

Insulin ResistanceAnimalsAntioxidantsDiet, High-FatDisease Models, AnimalHyperlipidemiasInflammationLarreaLipogenesisMaleMasoprocolMiceMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseObesityOxidative StressAntioxidantsMasoprocolHepatic fibrosisHepatic steatosisInsulin resistanceMetabolic syndromeNAFLDNordihydroguaiaretic acid

Identifiers

PMID31415794
PMCPMC7273809
OpenAlexW2967562334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.